Auteur/autrice : GRECC

Psychedelics, David E. Nichols, 2016

Psychedelics David E. Nichols Pharmacological Review, 2016, 68, 264–355 http://dx.doi.org/10.1124/pr.115.011478   Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .266 I. Introduction . . . . . . . . . . . . . . . . . . . . . . . [...]

Lire la suite

« Heureusement qu’il y a l’herbe ! », Anne Coppel, Chimères, 2014

« Heureusement qu’il y a l’herbe ! » Anne Coppel ERES | « Chimères », 2014/1 N° 82 | pages 33 à 42 https://www.cairn.inforevue-chimeres-2014-1-page-33.htm « On ne trouve pas trace dans les livres, ni ailleurs, du nom de Govan- Eremetus, ni du pays d’Archaos où il régna, entre la fin des Temps- Barbares et le commencement des Temps-Barbares. Pourtant quelque chose manque là, à la fois dans le temps et dans l’espace. À ce tournant mal éclairé de l’histoire, il y a comme un trou, des événements postérieurs restent inexpliqués. Les coordonnées ne se rejoignent pas ; à partir d’un certain point on les [...]

Lire la suite

Il y a herbe et herbe, Michka Seeliger-Chatelain, Chimères, 2014

Il y a herbe et herbe Michka SEELIGER-CHATELAIN ERES | « Chimères », 2014/1 N° 82 | pages 43 à 48 https://www.cairn.inforevue-chimeres-2014-1-page-43.htm   Jean-Philippe Cazier : Vous dites que fumer de l’herbe vous a permis d’échapper à une forme de rationalité trop stricte. Est-ce que vous diriez que le cannabis a rendu possible, pour vous, un nouveau rapport au monde et à soi, de produire une forme de subjectivité ? M. : Le mot « cannabis » est encore plus vague que le mot « vin ». Il y a un monde entre le gros rouge de base et un grand cru élevé avec amour. Le [...]

Lire la suite

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, Chung Mo Koo et al., 2017

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ? Chung Mo Koo, Hoon-Chul Kang Journal of Epilepsy Research, 2017, 7, 16-20. pISSN 2233-6249 / eISSN 2233-6257 www.kes.or.kr   Epilepsy is an important disease that affects brain function, particularly in those under 3 years old. Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since [...]

Lire la suite

Don’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy, Commentary, M. Scott Perry, 2019

Don’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy - Commentary M. Scott Perry Epilepsy Currents, 2019, Vol. 19, (2), 93-95 DOI: 10.1177/1535759719835671   Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med, 2018, 378, 1888-1897. Background : Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy. Methods : In this double-blind, placebo-controlled trial conducted [...]

Lire la suite

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, Richard J. Huntsman et al., 2019

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in  Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716   Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]

Lire la suite

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study, Darren Reithmeier et al., 2018

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y   Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]

Lire la suite

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome, Blathnaid McCoy et al., 2018

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir, Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III Annals of Clinical and Translational Neurology, 2018, 5, (9), 1077–1088 doi: 10.1002/acn3.621   Abstract Introduction : Both D9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug-resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD, yet there is a paucity of information on THC in epilepsy. Primary [...]

Lire la suite

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome, Bin GU et al., 2019 model mice,

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. Bin Gu, Manhua Zhu, Madison R. Glass, Marie Rougié, Viktoriya D. Nikolova, Sheryl S. Moy, Paul R. Carney, and Benjamin D. Philpot Journal of Clinical Investigation, 2019 Sep 10, pii: 130419. doi : 10.1172/JCI130419 PMID : 31503547 Abstract Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and [...]

Lire la suite

IACM-Bulletin du 27 Septembre 2019

IACM-Bulletin du 27 Septembre 2019 Science/Homme: La consommation de cannabis est associée à une réduction des infections due à une maladie bactérienne fréquemment attrapée dans les hôpitaux Science/Homme: La capsaïcine peut être utile dans le syndrome d'hyperémèse de cannabinoïde Science/Homme: Le THC peut être utile chez les patients souffrant de douleur gériatrique En bref Un coup d'œil sur le passé Science/Homme: La consommation de cannabis est associée à une réduction des infections due à une maladie bactérienne fréquemment attrapée dans les hôpitaux Lors d’une étude portant sur 59 824 patients, la consommation de cannabis [...]

Lire la suite